Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	HORŇÁK Tomáš SEMERÁD Lukáš ŽÁČKOVÁ Daniela WEINBERGEROVÁ Barbora ŠUSTKOVÁ Zuzana PROCHÁZKOVÁ Jiřina BELOHLAVKOVA Petra STEJSKAL Lukas ROHON Peter FABER Edgar ZAK Pavel MAYER Jiří RÁČIL Zdeněk
Year of publication	2020
Type	Article in Periodical
Magazine / Source	LEUKEMIA & LYMPHOMA
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1672054
Doi	http://dx.doi.org/10.1080/10428194.2019.1672054
Keywords	serum lipids; cardiovascular risk; nilotinib and imatinib therapy
Description	Tyrosine kinase inhibitors (TKI) have dramatically improved the prognosis of CML patients with life expectancy close to individuals without CML [1], and therefore the longterm safety of TKIs has become especially important due to the potential for lifelong treatment. Nilotinib (NILO) tends to have a negative effect on lipid [2] and glucose [3] metabolism, while imatinib (IMA) seems to improve [4] these abnormalities. Although the data appear convincing, the real impact of these changes on cardiovascular (CV) risk and the development of CV complications during TKI therapy have not yet been confirmed.
Related projects:	Mutační analýza primitivních buněčných populací u chronické myeloidní leukémie: za hranicí BCR-ABL1 Český národní uzel Evropské sítě infrastruktur klinického výzkumu (CZECRIN)